On April 5, 2026, Neurocrine Biosciences, Inc. announced its merger agreement with Soleno Therapeutics, planning to acquire shares at $53.00 each, contingent on certain conditions being met.
AI Assistant
NEUROCRINE BIOSCIENCES INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.